Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti–PD-1 treatment with nivolumab
Author:
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Neurology (clinical),Oncology
Reference3 articles.
1. Prospects of immune checkpoint modulators in the treatment of glioblastoma
2. Immunotherapy for glioblastoma
3. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth;Scientific Reports;2024-08-08
2. Exploring MAP2K3 as a prognostic biomarker and potential immunotherapy target in glioma treatment;Frontiers in Neurology;2024-06-13
3. Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches;International Journal of Molecular Sciences;2024-05-26
4. A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives;Neurological Sciences;2024-02-03
5. SOMATIC DEFICIENT MISMATCH REPAIR ASSESSED BY IMMUNOHISTOCHEMISTRY AND CLINICAL FEATURES IN BRAZILIAN GLIOBLASTOMA PATIENTS;Experimental Oncology;2023-12-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3